Neha Krishnamohan is currently the chief financial officer and executive vice president of corporate development at Artiva Biotherapeutics, with more than 15 years of experience in healthcare investment banking, financial and strategic leadership. Neha was most recently the chief financial officer and executive vice president of corporate development at Kinnate Biopharma Inc., a clinical stage precision oncology company where she led the company’s financial operations, business development, and investor relations / communications functions. Neha played a lead role in Kinnate’s exploration of strategic alternatives, which resulted in a successful asset sale to Pierre Fabre Laboratories and the sale of Kinnate to XOMA Corporation. Prior to Kinnate, Neha was a vice president in the Healthcare Investment Banking Group and a member of the Mergers and Acquisitions (M&A) Group within the Investment Banking Division at Goldman Sachs. While at Goldman Sachs, she established herself as a senior leader in the healthcare coverage group, working with a variety of biopharmaceutical boards and management teams on a broad range of strategic financial matters, executing financings as well as leading M&A transactions. Neha has successfully executed over $100 billion in transactions in the biopharmaceutical, medical technology, and tools/diagnostics sectors. Neha is currently on the board of Arcutis Biotherapeutics, Inc. and serves as a member of their audit committee. Neha holds a B.S.E in biomedical engineering and economics from Duke University.